JP2016525130A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525130A5 JP2016525130A5 JP2016528335A JP2016528335A JP2016525130A5 JP 2016525130 A5 JP2016525130 A5 JP 2016525130A5 JP 2016528335 A JP2016528335 A JP 2016528335A JP 2016528335 A JP2016528335 A JP 2016528335A JP 2016525130 A5 JP2016525130 A5 JP 2016525130A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- pharmaceutical composition
- groups
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 3
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims 3
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims 3
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 2
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/080105 | 2013-07-25 | ||
| PCT/CN2013/080105 WO2015010297A1 (en) | 2013-07-25 | 2013-07-25 | Therapeutically active compounds and their methods of use |
| PCT/CN2014/082869 WO2015010626A1 (en) | 2013-07-25 | 2014-07-24 | Therapeutically active compounds and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019001587A Division JP6640390B2 (ja) | 2013-07-25 | 2019-01-09 | 治療活性化合物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525130A JP2016525130A (ja) | 2016-08-22 |
| JP2016525130A5 true JP2016525130A5 (enExample) | 2017-08-31 |
Family
ID=52392611
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528335A Withdrawn JP2016525130A (ja) | 2013-07-25 | 2014-07-24 | 治療活性化合物及びその使用 |
| JP2019001587A Active JP6640390B2 (ja) | 2013-07-25 | 2019-01-09 | 治療活性化合物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019001587A Active JP6640390B2 (ja) | 2013-07-25 | 2019-01-09 | 治療活性化合物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3024824A4 (enExample) |
| JP (2) | JP2016525130A (enExample) |
| AR (1) | AR097082A1 (enExample) |
| CA (1) | CA2918500C (enExample) |
| MX (2) | MX2016000696A (enExample) |
| TW (1) | TWI662023B (enExample) |
| WO (2) | WO2015010297A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6272833B2 (ja) * | 2013-04-04 | 2018-01-31 | 武田薬品工業株式会社 | 複素環化合物 |
| CN109071429B (zh) * | 2016-03-22 | 2021-04-02 | 正大天晴药业集团股份有限公司 | 丙啶磺酰胺类化合物及其使用方法 |
| US11111240B2 (en) * | 2016-03-22 | 2021-09-07 | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. | Sultam compound and application method thereof |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| CN111163776A (zh) * | 2017-06-12 | 2020-05-15 | 安吉奥斯医药品有限公司 | 使用组合疗法治疗脑肿瘤的方法 |
| TW202440123A (zh) | 2017-06-12 | 2024-10-16 | 法商施維雅藥廠 | 以組合療法治療腦瘤之方法 |
| WO2019057142A1 (zh) * | 2017-09-22 | 2019-03-28 | 正大天晴药业集团股份有限公司 | 一种内磺酰胺化合物结晶 |
| WO2019071073A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| AU2019356011B2 (en) | 2018-10-05 | 2025-02-06 | Forma Therapeutics, Inc. | Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors |
| US12358886B2 (en) | 2019-08-09 | 2025-07-15 | Artios Pharma Limited | Heterocyclic compounds for use in the treatment of cancer |
| TW202120486A (zh) * | 2019-08-09 | 2021-06-01 | 英商阿帝歐斯製藥有限公司 | 新穎化合物 |
| CN111349081B (zh) * | 2020-04-28 | 2021-01-15 | 宁波大学科学技术学院 | 一种Ivosidenib及其中间体的手性合成方法 |
| CN116332905B (zh) * | 2021-12-23 | 2025-07-08 | 上海翊石医药科技有限公司 | (s)-n-苯基-1-(吡啶-2-基)吡咯烷-2-甲酰胺衍生物 |
| WO2023125918A1 (zh) * | 2021-12-30 | 2023-07-06 | 上海湃隆生物科技有限公司 | 一种DNA聚合酶theta抑制剂及其应用 |
| CA3247154A1 (en) | 2022-01-10 | 2023-07-13 | Recludix Pharma, Inc. | STAT MODULATORS AND THEIR USES |
| CN117069618A (zh) * | 2022-12-13 | 2023-11-17 | 常州制药厂有限公司 | 一种利用微通道反应器制备阿布西替尼关键中间体的方法 |
| CN118221638B (zh) * | 2022-12-19 | 2025-09-19 | 艾立康药业股份有限公司 | 作为DNA聚合酶Theta抑制剂的杂环化合物 |
| WO2024205311A1 (en) * | 2023-03-31 | 2024-10-03 | Avelos Therapeutics Inc. | Substituted sultam compound derivatives and their pharmaceutical use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2012009678A1 (en) * | 2010-07-16 | 2012-01-19 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their method of use |
| EP2771337B1 (en) * | 2011-09-27 | 2017-08-02 | Novartis AG | 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh |
| CN102659765B (zh) * | 2011-12-31 | 2014-09-10 | 沈阳药科大学 | 嘧啶及三嗪类化合物的制备方法和应用 |
| CA2860858A1 (en) * | 2012-01-19 | 2013-07-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9474779B2 (en) * | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
-
2013
- 2013-07-25 WO PCT/CN2013/080105 patent/WO2015010297A1/en not_active Ceased
-
2014
- 2014-07-24 EP EP14828790.7A patent/EP3024824A4/en not_active Withdrawn
- 2014-07-24 JP JP2016528335A patent/JP2016525130A/ja not_active Withdrawn
- 2014-07-24 CA CA2918500A patent/CA2918500C/en active Active
- 2014-07-24 WO PCT/CN2014/082869 patent/WO2015010626A1/en not_active Ceased
- 2014-07-24 MX MX2016000696A patent/MX2016000696A/es unknown
- 2014-07-25 TW TW103125441A patent/TWI662023B/zh active
- 2014-07-25 AR ARP140102794A patent/AR097082A1/es unknown
-
2016
- 2016-01-18 MX MX2021001425A patent/MX2021001425A/es unknown
-
2019
- 2019-01-09 JP JP2019001587A patent/JP6640390B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525130A5 (enExample) | ||
| JP2015509098A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2017530959A5 (enExample) | ||
| JP2016006118A5 (enExample) | ||
| JP2018510139A5 (enExample) | ||
| JP2016518328A5 (enExample) | ||
| JP2016500661A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2017506666A5 (enExample) | ||
| JP2014193925A5 (enExample) | ||
| CY1117453T1 (el) | Νεες ενωσεις τροποποιησης toy fxr (nr1h4) | |
| JP2011513410A5 (enExample) | ||
| JP2011137045A5 (enExample) | ||
| JP2016528273A5 (enExample) | ||
| JP2009541236A5 (enExample) | ||
| JP2018519343A5 (enExample) | ||
| JP2014015465A5 (enExample) | ||
| SI3009431T1 (en) | 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer | |
| JP2016525075A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2019531279A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| JP2020532545A5 (enExample) |